Background

Ibrutinib is an oral inhibitor of Bruton tyrosine kinase that is approved by the United States Food and Drug Administration for several lymphoproliferative disorders and chronic graft-versus-host disease.

Objective

To characterize cutaneous eruptions arising from ibrutinib and highlight overlap with epidermal growth factor receptor (EGFR) inhibitor–induced dermatologic adverse events.

Methods

Single-center retrospective cohort of patients referred to the Skin Toxicities Program for treatment of cutaneous eruptions while taking ibrutinib.

Results

Among 19 patients, cutaneous eruptions manifested as facial-predominant papulopustular eruptions, petechiae, or ecchymoses, photosensitivity, panniculitis, xerosis, and clinical staphylococcal overgrowth. Most patients were able to continue ibrutinib therapy with focused treatment of their cutaneous toxicities.

Limitations

This study represents cases at a single tertiary care center and is limited to patients referred for toxicity.

Conclusions

With the exception of petechiae, the cutaneous toxicities of ibrutinib overlap with those associated with selective EGFR inhibitors. We observed that these reactions can be successfully managed using approaches for EGFR inhibitor–induced cutaneous adverse events.

中文翻译：

---

伊布替尼引起的皮疹类似于表皮生长因子受体抑制剂引起的皮肤病学不良事件

背景

Ibrutinib 是一种布鲁顿酪氨酸激酶的口服抑制剂，已被美国食品和药物管理局批准用于治疗多种淋巴增生性疾病和慢性移植物抗宿主病。

客观的

表征由依鲁替尼引起的皮疹，并突出与表皮生长因子受体 (EGFR) 抑制剂诱导的皮肤病学不良事件的重叠。

方法

单中心回顾性队列患者在服用依鲁替尼期间转诊至皮肤毒性项目治疗皮疹。

结果

在 19 名患者中，皮疹表现为面部为主的丘疹脓疱、瘀斑或瘀斑、光敏性、脂膜炎、干燥症和临床葡萄球菌过度生长。大多数患者能够继续依鲁替尼治疗，重点治疗其皮肤毒性。

限制

这项研究代表了一个单一的三级医疗中心的案例，并且仅限于因毒性而转诊的患者。

结论

除瘀点外，依鲁替尼的皮肤毒性与选择性 EGFR 抑制剂相关的皮肤毒性重叠。我们观察到，使用 EGFR 抑制剂诱发的皮肤不良事件的方法可以成功控制这些反应。